Skip to content
Peptigraph home

Cagrilintide and Semaglutide Together: What Is Known

Cagrilintide and Semaglutide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Amylin analogInvestigational (CagriSema component)CagrilintideInvestigational amylin analogue, not FDA-approved; a meta-analysis found cagrilintide monotherapy reduced body weight by a mean difference of -6.08%.[16]GLP-1 & metabolicGLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[17]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

  • REDEFINE 1: randomized trial of cagrilintide and semaglutide co-administered, versus each alone and placebo. · PMID 40544433
  • REDEFINE 2: co-administration of cagrilintide and semaglutide (CagriSema) in adults with type 2 diabetes. · PMID 40544432
  • Phase 1b randomized trial of multiple doses of cagrilintide given together with semaglutide 2.4 mg. · PMID 33894838
Cagrilintide is not FDA approved. The studies above describe research settings, not a recommendation to combine them. Ask the prescriber who manages both.
Each component

Side by side

Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldCagrilintideSemaglutide
ClassAmylin analogGLP-1 agonist
Also calledcagri, cagsema, Ozempic, Wegovy, Rybelsus, Wegovy pill
FDA statusInvestigational (CagriSema component)FDA approved (Ozempic, Wegovy, Rybelsus)
WADAProhibited by WADA (S0)Cagrilintide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Half-life159-195 h (with semaglutide 2.4 mg co-administered)subcutaneous · Lancet 2021, PMID 33894838approximately 1 weeksubcutaneous · FDA label (Ozempic)
Human studies we summarised5 human (5 randomized or controlled) of 8 summarised23 human (19 randomized or controlled) of 27 summarised
Typical study doses
Vial sizes sold2.5 mg, 5 mg, 10 mg2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg

Co-administration trials of cagrilintide 2.4 mg and semaglutide 2.4 mg

REDEFINE 1 assigned adults, in a 21:3:3:7 ratio, to semaglutide 2.4 mg with cagrilintide 2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo.[14]

A phase 1b co-administration trial reported that cagrilintide exposure rose in proportion to its dose and did not alter semaglutide's exposure or elimination.[5]

REDEFINE 1 randomised 3417 adults; at week 68 the combination cut body weight by 20.4% versus 3.0% on placebo.[14]

In that trial gastrointestinal events were reported by 79.6% of the combination group against 39.9% on placebo, mostly transient and mild to moderate.[14]

In REDEFINE 2, body weight changed by -13.7% on the combination and -3.4% on placebo.[15]

REDEFINE 5 was a phase 3a trial run at 21 sites in Japan and one site in Taiwan.[19]

REDEFINE 5 compared the combination with semaglutide alone and found -18.4% versus -11.9% at week 68.[19]

What the combination adds in side effects

In the meta-analysis, overall and serious adverse events were comparable between the combination and semaglutide, but the combination caused more administration-site conditions and nausea.[20]

The same meta-analysis found the combination produced significantly greater percentage weight loss than semaglutide across randomised trials with 3545 participants.[20]

The same meta-analysis found cagrilintide alone carried a higher risk of serious adverse events than semaglutide.[20]

Approval and compounding

The Wegovy label says use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.[21]

CagriSema has no FDA-approved product; a Drugs@FDA search for it returned no matches.[22]

FDA says cagrilintide cannot be used in compounding under federal law.[23]

Common questions

Is CagriSema better than semaglutide?

In REDEFINE 5 it produced more weight loss than semaglutide alone: -18.4% against -11.9%.[19]

Is cagrilintide with semaglutide (CagriSema) approved?

No: a Drugs@FDA search for CagriSema returned no match.[22]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  6. 6Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  7. 7Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  8. 8Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  11. 11Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  12. 12Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  13. 13PubMed search: (cagrilintide[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
  15. 15Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
  16. 16Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
  17. 17Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  18. 18Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
  19. 19Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
  20. 20Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes, obesity & metabolism · 2026PMID 41834765Accessed 2 Oct 2026
  21. 21WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  22. 22Drugs@FDA (openFDA) search: active ingredient "cagrisema"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  23. 23Official web pageOfficial web page · web page

Found an error? Report a correction.